Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

October 19, 2020

Study Completion Date

March 7, 2022

Conditions
Colorectal Cancer
Interventions
DRUG

Oral Tablet: Cabozantinib

Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.

Trial Locations (10)

19001

Jefferson Abington Hospital, Abington

19107

Thomas Jefferson University, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

80045

Universtiy of Colorado Denver, Aurora

80124

Lone Tree Health Center, Lone Tree

85724

University of Arizona, Tucson

90033

Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles

98122

Swedish Medical Center, Seattle

02114

Massachusetts General Hospital Cancer Center, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

Academic Thoracic Oncology Medical Investigators Consortium

INDUSTRY

NCT03542877 - Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter